Xenon Pharmaceuticals Azioni (NASDAQ: XENE)

Ultime notizie per Xenon Pharmaceuticals (NASDAQ:XENE) Azioni

Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a neuroscience-focused biopharmaceutical company committed to improving the lives of people living with neurological and psychiatric disorders. It is advancing a novel product pipeline to address areas of high unmet medical need, including epilepsy and depression. The product candidates of the group include XEN1101, NBI-921352, and XEN496 for Epilepsy and Nav1.7 oral inhibitors for Pain.

Xenon Pharmaceuticals Inc. - Common Shares

Xenon Pharmaceuticals Inc

Xenetic Biosciences Inc

Xenetic Biosciences Inc Warrants (19/07/2024)

U.S. stocks traded mixed midway through trading, with the Dow Jones index falling around 200 points on Tuesday.
The Dow traded down 0.49% to 42,203.63 while the NASDAQ gained 1.74% to 19,033.50. The S&amp;P 500 also rose, gaining, 0.86% to 5,894.52.
Check This Out: <a href="https://www.benzinga.com/25/05/45373483/top-2-materials-stocks-that-may-keep-you-up-at-night-in-may">Top 2 Materials Stocks That May Keep You Up At Night In May</a>
Leading and Lagging Sectors Information technology shares jumped by 2.3% on Tuesday.
In trading on Tuesday, health care stocks fell by 2.5%.
Top Headline
Consumer prices in the U.S. eased faster than expected in April, with fresh tariffs introduced by President Donald Trump appearing not to have a swift and tangible impact on the cost of living.
The Consumer Price Index (CPI) was 2.3% higher compared to a year ago, the Bureau of Labor Statistics said Tuesday, compared to economists&#8217; expectations of 2.4% and the previous reading.
The monthly gain was 0.2%, rebounding from a prior decline of 0.1%, yet falling short of a 0.3% forecasted.
Equities Trading UP &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;
<ul class="wp-block-list">
<li>HCW Biologics Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HCWB#NASDAQ">HCWB</a>) shares shot up 165% to $14.01 after the company announced it presented studies on HCW9206.</li>
<li>Shares of Microvast Holdings, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MVST#NASDAQ">MVST</a>) got a boost, surging 33% to $3.1749 after the company reported better-than-expected first-quarter sales results.</li>
<li>Lobo EV Technologies Ltd. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/LOBO#NASDAQ">LOBO</a>) shares were also up, gaining 116% to $1.6001 after the company issued a year-over-year increase in its FY25 revenue guidance.</li>
</ul>
Equities Trading DOWN
<ul class="wp-block-list">
<li>Xenon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) shares dropped 17% to $29.90 following first-quarter financial results.</li>
<li>Shares of Affimed N.V. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AFMD#NASDAQ">AFMD</a>) were down 81% to $0.1345 after Leerink Partners downgraded the stock from Outperform to Market Perform and cut its price target from $5 to $0.39.</li>
<li>Halozyme Therapeutics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/HALO#NASDAQ">HALO</a>) was down, falling 26% to $49.26. Leerink Partners downgraded Halozyme Therapeutics from Market Perform to Underperform and announced a $47 price target.</li>
</ul>
Commodities In commodity news, oil traded up 2.9% to $63.75 while gold traded up 0.8% at $3,253.80.
Silver traded up 1.6% to $33.130 on Tuesday, while copper rose 2.1% to $4.7180.
Euro zone
European shares were mostly higher today. The eurozone's STOXX 600 gained 0.12%, while Spain's IBEX 35 Index rose 0.83%. London's FTSE 100 fell 0.02%, Germany's DAX 40 gained 0.31% and France's CAC 40 gained 0.30% during the session.
Asia Pacific Markets
Asian markets closed mostly higher on Tuesday, with Japan's Nikkei gaining 1.43%, Hong Kong's Hang Seng Index dipping 1.87%, China's Shanghai Composite Index gaining 0.17% and India's BSE Sensex falling 1.55%.
Economics
The annual inflation rate in the US slowed to 2.3% in April from 2.4% in the previous month and versus market estimates of 2.4%.
Now Read This: 
<ul class="wp-block-list">
<li><a href="https://www.benzinga.com/25/05/45347296/this-target-analyst-turns-bearish-here-are-top-5-downgrades-for-monday">This Target Analyst Turns Bearish; Here Are Top 5 Downgrades For Monday</a> </li>
</ul>
Photo via Shutterstock

Equities

News

Eurozone

Commodities

Intraday Update

Markets

Trading Ideas

AFMD

HALO

HCWB

LOBO

MVST

XENE

Crude Oil Gains 3%; US Inflation Eases In April

HC Wainwright &amp; Co. analyst Douglas Tsao reiterates Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $53 price target.

Price Target

Reiteration

Analyst Ratings

HC Wainwright & Co. Reiterates Buy on Xenon Pharmaceuticals, Maintains $53 Price Target

Needham analyst Serge Belanger maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $60 to $55.

Needham Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $55

Chardan Capital analyst Rudy Li maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and maintains $55 price target.

Chardan Capital Maintains Buy on Xenon Pharmaceuticals, Maintains $55 Price Target

WIIM

Xenon Pharmaceuticals shares are trading lower. The company reported Q1 financial results.

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.83) per share which beat the analyst consensus estimate of $(0.92) by 9.78 percent. This is a 33.87 percent decrease over losses of $(0.62) per share from the same period last year. The company reported quarterly sales of $7.50 million which beat the analyst consensus estimate of $1.11 million by 577.42 percent.

Earnings

Earnings Beats

Xenon Pharmaceuticals Q1 EPS $(0.83) Beats $(0.92) Estimate, Sales $7.50M Beat $1.11M Estimate

ACHC

ACHR

ACNT

AGEN

AIRJ

ALLT

ALTI

AMBC

AMPY

APEI

AQST

ARCT

ARWR

ASRT

ASYS

AUPH

BATRA

BATRK

Mobile Infrastructure Corporation Common Stock

BEEP

BETR

Bakkt Holdings, Inc. Class A Common Stock

BKKT

BLDE

BLNK

CATX

CEPU

CHGG

CHRS

CLLS

CLPR

CMCL

CMPO

CNNE

CNTY

CPSS

CTMX

CTRI

CWCO

DOLE

EDIT

EXOD

FGEN

FOXA

FRPH

FTEK

FTRE

GAIA

GETY

GPRO

GRDN

HBIO

HFFG

HNRG

IHRT

IMNN

INDI

ISPR

KBDC

KPTI

KSPI

LAND

LEGH

LINC

LSEA

LTBR

METC

Ramaco Resources, Inc. - Class B Common Stock

METCB

MFIC

MLNK

MLYS

MNDY

MODG

MRVI

MVIS

NMRA

NOTE

NPWR

NRGV

NRXS

Earnings Scheduled For May 12, 2025

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) is gearing up to announce its quarterly earnings on Monday, 2025-05-12. Here's a quick overview of what investors should know before the release.
Analysts are estimating that Xenon Pharmaceuticals will report an earnings per share (EPS) of $-0.91.
The announcement from Xenon Pharmaceuticals is eagerly anticipated, with investors seeking news of surpassing estimates and favorable guidance for the next quarter.
It's worth noting for new investors that guidance can be a key determinant of stock price movements.
<h3>Historical Earnings Performance</h3>
During the last quarter, the company reported an EPS missed by $0.00, leading to a 3.37% drop in the share price on the subsequent day.
Here's a look at Xenon Pharmaceuticals's past performance and the resulting price change:

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Q4 2024</th>
<th>Q3 2024</th>
<th>Q2 2024</th>
<th>Q1 2024</th>
</tr>
</thead>
<tbody>
<tr>
<td>EPS Estimate</td>
<td>-0.84</td>
<td>-0.81</td>
<td>-0.70</td>
<td>-0.66</td>
</tr>
<tr>
<td>EPS Actual</td>
<td>-0.84</td>
<td>-0.81</td>
<td>-0.75</td>
<td>-0.62</td>
</tr>
<tr>
<td>Price Change %</td>
<td>-3.0%</td>
<td>-3.0%</td>
<td>-3.0%</td>
<td>-5.0%</td>
</tr>
</tbody>
</table>

<img src="https://www.benzinga.com/files/images/story/2025/1746799341_0.png" alt="eps graph" />
<h3>Tracking Xenon Pharmaceuticals's Stock Performance</h3>
Shares of Xenon Pharmaceuticals were trading at $35.54 as of May 08. Over the last 52-week period, shares are down 10.8%. Given that these returns are generally negative, long-term shareholders are likely upset going into this earnings release. 
<a href="https://www.benzinga.com/quote/XENE/earnings">To track all earnings releases for Xenon Pharmaceuticals visit their earnings calendar on our site.</a>
This article was generated by Benzinga's automated content engine and reviewed by an editor.

What to Expect from Xenon Pharmaceuticals's Earnings

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Jefferies analyst John Hecht downgraded Discover Financial Services (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DFS#NYSE">DFS</a>) from Buy to Hold and announced a $180 price target. Discover Financial shares closed at $188.12 on Tuesday. <a href="https://www.benzinga.com/quote/DFS/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Keybanc analyst Philip Gibbs downgraded the rating for Materion Corporation (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MTRN#NYSE">MTRN</a>) from Overweight to Sector Weight. Materion shares closed at $78.28 on Tuesday. <a href="https://www.benzinga.com/quote/MTRN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>JP Morgan analyst Matthew Lofting downgraded the rating for Equinor ASA (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EQNR#NYSE">EQNR</a>) from Overweight to Neutral. Equinor shares closed at $23.27 on Tuesday. <a href="https://www.benzinga.com/quote/EQNR/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>BMO Capital analyst John McNulty downgraded Tronox Holdings plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TROX#NYSE">TROX</a>) from Outperform to Market Perform and lowered the price target from $13 to $7. Tronox shares closed at $5.31 on Tuesday. <a href="https://www.benzinga.com/quote/AFRM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Needham analyst James Ricchiuti downgraded the rating for FARO Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FARO#NASDAQ">FARO</a>) from Buy to Hold and maintained the price target of $38. Faro Technologies shares closed at $42.36 on Tuesday. <a href="https://www.benzinga.com/quote/MSFT/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying DFS stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="576" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71-1024x576.png" alt="" class="wp-image-905473" style="width:532px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71-1024x576.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71-300x169.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71-768x432.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07081344/image-71.png 1138w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Downgrades

Pre-Market Outlook

EQNR

FARO

MTRN

TROX

This Discover Financial Services Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our <a href="https://www.benzinga.com/analyst-stock-ratings">analyst ratings page</a>.
<ul>
<li>Seaport Global analyst John Mazzoni initiated coverage on Waste Management, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WM#NYSE">WM</a>) with a Neutral rating. Waste Management shares closed at $234.07 on Tuesday. <a href="https://www.benzinga.com/quote/WM/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital analyst Rudy Li initiated coverage on Praxis Precision Medicines, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PRAX#NASDAQ">PRAX</a>) with a Buy rating and announced a price target of $80. Praxis Precision Medicine shares closed at $35.17 on Tuesday. <a href="https://www.benzinga.com/quote/PRAX/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst John Mazzoni initiated coverage on Waste Connections, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WCN#NYSE">WCN</a>) with a Buy rating and announced a price target of $220. Waste Connections shares closed at $198.38 on Tuesday. <a href="https://www.benzinga.com/quote/WCN/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Chardan Capital analyst Rudy Li initiated coverage on Xenon Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy rating and announced a price target of $55. Xenon Pharmaceuticals shares closed at $35.18 on Tuesday. <a href="https://www.benzinga.com/quote/XENE/analyst-ratings">See how other analysts view this stock</a>.</li>
<li>Seaport Global analyst John Mazzoni initiated coverage on Republic Services, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RSG#NYSE">RSG</a>) with a Buy rating and announced a price target of $270. Republic Services shares closed at $250.85 on Tuesday. <a href="https://www.benzinga.com/quote/RSG/analyst-ratings">See how other analysts view this stock.</a></li>
</ul>
Considering buying WCN stock? Here&#8217;s what analysts think: 
<figure class="wp-block-image size-large is-resized"><img loading="lazy" decoding="async" width="1024" height="590" src="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07075043/image-69-1024x590.png" alt="" class="wp-image-905430" style="width:597px;height:auto" srcset="https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07075043/image-69-1024x590.png 1024w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07075043/image-69-300x173.png 300w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07075043/image-69-768x443.png 768w,https://editorial-assets.benzinga.com/wp-content/uploads/2025/05/07075043/image-69.png 1105w" sizes="(max-width: 1024px) 100vw, 1024px" /></figure>
Read This Next: 
<ul>
<li><a href="https://www.benzinga.com/25/05/45219636/top-2-energy-stocks-that-are-ticking-portfolio-bombs">Top 2 Energy Stocks That Are Ticking Portfolio Bombs</a> </li>
</ul>
Photo via Shutterstock

Initiation

PRAX

This Waste Connections Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Wednesday

Chardan Capital analyst Rudy Li initiates coverage on Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy rating and announces Price Target of $55.

Chardan Capital Initiates Coverage On Xenon Pharmaceuticals with Buy Rating, Announces Price Target of $55

Goldman Sachs analyst Paul Choi maintains Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) with a Buy and lowers the price target from $60 to $52.

Goldman Sachs Maintains Buy on Xenon Pharmaceuticals, Lowers Price Target to $52

Xenon Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/XENE#NASDAQ">XENE</a>) reported quarterly losses of $(0.84) per share which beat the analyst consensus estimate of $(0.86) by 2.33 percent. This is a 31.25 percent decrease over losses of $(0.64) per share from the same period last year.

Xenon Pharmaceuticals Q4 2024 GAAP EPS $(0.84) Beats $(0.86) Estimate

AAON

ABCL

ACEL

ACIC

ACIW

ADSK

AIRG

ALEX

ALHC

ALKT

ALTM

AMBP

AMPH

AMRC

AMWD

ARGX

ARLO

ARRY

ASTH

AVPT

BBWI

BCSF

BECN

BLND

BWMX

CABO

CARS

CCOI

CDXS

CLCO

CLOV

CMBT

CMLS

CMPS

CODI

COLL

CRDF

CRNX

CRON

CSTL

CTKB

CUBE

CVEO

CYTK

DAIO

DCGO

DELL

DUOL

ECVT

EFXT

ERIE

Embraer-Empresa Brasileira De Aeronautica

ESEA

ESTC

EVRG

EXFY

FIGS

FOXF

FTDR

FWONA

FWONK

Earnings Scheduled For February 27, 2025

Comments

Xenon Pharmaceuticals

Notizie

Ultime notizie per Xenon Pharmaceuticals (NASDAQ:XENE) Azioni

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO